ClinicalTrials.Veeva

Menu
F

Fundacion Respirar | Clinical Independency Research

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

BMS-986278
Tarlatamab
Nivolumab
Bemarituzumab
LY3009104
Baricitinib
Povorcitinib

Parent organization

This site is a part of Fundacion Respirar

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 6 total trials

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

Enrolling
Moderate to Severe Asthma
Drug: ICS-LABA
Other: placebo

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: BMS-986278 Placebo
Drug: BMS-986278

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Enrolling
Progressive Pulmonary Fibrosis
Drug: BMS-986278 Placebo
Drug: BMS-986278

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...

Active, not recruiting
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Other: Placebo
Drug: Nivolumab

The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS).

Enrolling
Small Cell Lung Cancer
Limited Stage Small Cell Lung Cancer
Drug: Placebo
Drug: Tarlatamab

Trial sponsors

Amgen logo
Bristol-Myers Squibb (BMS) logo
Incyte logo
Lilly logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems